Shao Lei, Liu Wanqiu, Zhang Chunyan, Ma Wei, Yu Xiao, Han Jing, Wang Xiaojuan
Department of Gynecology, the Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, China.
Qiqihar City Hospital of Traditional Chinese Medicine South Department of Gynecology, Qiqihar, China.
Iran J Public Health. 2024 Apr;53(4):855-866. doi: 10.18502/ijph.v53i4.15562.
We started with RNA-seq analysis and aimed to investigate the possibility of secretory protein matrix metalloproteinase-3() as a new diagnosis and therapeutic target in cervical cancer.
The study was conducted on Nov 2021 at the Second Affiliated Hospital of Qiqihar Medical University, Qiqihar, China. Through conjoint analysis of gene expression data as well as survival rate data, we explored the potential secretary proteins associated with cervical cancer carcinogenesis. One hundred patients aged 38-72 years with clinical stage I-IV cervical cancer, and 100 age-matched healthy women were included. The expression changes in serum of clinical patients was detected. We knockdown or overexpressed the secretory proteins then explored its influence on biological function of cervical cancer cells.
By cross-analysis of The Cancer Genome Atlas (TCGA) database and MetazSecKB database, gene was most significantly upregulated in cervical cancer patients ( < 0.05). Furthermore, protein was remarkably increased in the serum of clinical cervical cancer patients and decreased after receiving treatment. Overexpression of in HT-3 cells or culturing new cells using the supernatant of the medium after overexpression could increase cell viability ( < 0.05) as well as proliferation ( < 0.05). Knockdown of reduced the phosphorylation of PI3K as well as AKT proteins, while the PI3K phosphorylation inhibitors could suppress the impact of on increasing cell proliferation as well as viability.
could be an underlying target for early diagnosis and treat cervical cancer in the future.
我们从RNA测序分析入手,旨在研究分泌蛋白基质金属蛋白酶-3( )作为宫颈癌新的诊断和治疗靶点的可能性。
该研究于2021年11月在中国齐齐哈尔齐齐哈尔医学院附属第二医院进行。通过对基因表达数据和生存率数据的联合分析,我们探索了与宫颈癌发生相关的潜在分泌蛋白。纳入了100例年龄在38 - 72岁、临床分期为I - IV期的宫颈癌患者以及100例年龄匹配的健康女性。检测了临床患者血清中的表达变化。我们敲低或过表达分泌蛋白,然后探索其对宫颈癌细胞生物学功能的影响。
通过对癌症基因组图谱(TCGA)数据库和MetazSecKB数据库的交叉分析, 基因在宫颈癌患者中上调最为显著( < 0.05)。此外,临床宫颈癌患者血清中的 蛋白显著增加,治疗后降低。在HT - 3细胞中过表达 或使用过表达 后的培养基上清培养新细胞可增加细胞活力( < 0.05)以及增殖( < 0.05)。敲低 可降低PI3K以及AKT蛋白的磷酸化,而PI3K磷酸化抑制剂可抑制 对增加细胞增殖和活力的影响。
可能是未来早期诊断和治疗宫颈癌的潜在靶点。